Pfizer Ends its COVID-19 Vaccine Trial with a 95% Success Rate

The final results from the COVID-19 vaccine of Pfzier Inc’s trial showed that the shot had a 95% success rate and two months of safety data.

The final results from the COVID-19 vaccine of Pfzier Inc’s trial showed that the shot had a 95% success rate and two months of safety data. 

The COVID-19 vaccine results have paved the way for Pfizer Inc. to apply for an emergency U.S. authorization within days. 

Pfzier said that there were 170 COVID-19 cases in its trial of more than 43,000 volunteers.

Only eight (8) people had been given the vaccine shot rather than a placebo, which means that the vaccine had a 95% efficacy rate.

Out of the 10 people who have developed severe COVID-19 symptoms, only one was able to receive the vaccine. 

Pfizer is expected to produce as many as 50 million vaccine doses this year in order to protect at least 25 million people, and then produce over 1.3 billion doses in 2021. 


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.